Preclinical antihypertensive efficacy and immunogenicity in humans of a vaccine against angiotensin II based on virus-like particles (VLPs)

Παρόμοια τεκμήρια

• A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.
  ανά: Ambühl, P, κ.ά.
  Έκδοση: (2007)
• Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.
  ανά: Tissot, A, κ.ά.
  Έκδοση: (2008)
• CYT006-AngQb, a vaccine against hypertension targeting angiotensin II, reduces early-morning and day-time blood pressure
  ανά: Tissot, A, κ.ά.
  Έκδοση: (2007)
• Vaccination against angiotensin II reduces day-time ambulatory blood pressure: Results of a randomized placebo-controlled phase IIA study with CYT006-ANGQB
  ανά: Tissot, A, κ.ά.
  Έκδοση: (2007)
• Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults.
  ανά: Kündig, T, κ.ά.
  Έκδοση: (2006)